Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lunai Bioworks Inc. (LNAI : NSDQ)

• Company Description    Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company. Lunai Bioworks Inc., formerly known as RENOVARO INC, is based in LOS ANGELES. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $1.08 Daily Weekly Monthly 20 Day Moving Average: 269,972 shares Shares Outstanding: 23.18 (millions) Market Capitalization: $25.03 (millions) Beta: 0.39 52 Week High: $21.00 52 Week Low: $0.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.99% -18.80% 12 Week -58.22% -61.63% Year To Date -87.07% -88.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2080 Century Park East Suite 906 - Los Angeles,CA 90067 USA ph: 305-918-1980 fax: - renb@mzgroup.us http://www.renovarogroup.com

• General Corporate Information    Officers David Weinstein - Chief Executive Officer Nathen Fuentes - Chief Financial Officer Douglas W. Calder - Director James A. McNulty - Director Mark Collins - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: 29350E203 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 23.18 Most Recent Split Date: 9.00 (0.10:1) Beta: 0.39 Market Capitalization: $25.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: 100.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -222.12 03/31/25 - -60.38 ROA 09/30/25 - - 06/30/25 - -152.88 03/31/25 - -47.04 Current Ratio 09/30/25 - - 06/30/25 - 0.04 03/31/25 - 0.13 Quick Ratio 09/30/25 - - 06/30/25 - 0.04 03/31/25 - 0.13 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -1.24 03/31/25 - 5.44 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00

Powered by Zacks Investment Research ©